Contact Us
Drug Search Results
More Filters [+]

Ruxolitinib

Alternative Names: ruxolitinib, incb018424, jakavi, jakafi, inc 424, inc424, inc-424, opzelura
Latest Update: 2025-01-08
Latest Update Note: Clinical Trial Update

Product Description

Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD.

Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor,STAT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Myelofibrosis | Polycythemia | Thrombocythemia, Essential | Polycythemia Vera | Dermatitis | Dermatitis, Atopic | Vitiligo

Known Adverse Events: Dizziness | Headache | Anemia | Thrombocytopenia | Dermatitis | Erythema | Folliculitis | Urticaria | Nasopharyngitis | Pharyngitis | Tonsillitis | Dermatitis, Atopic | Pruritus | Vitiligo | Bronchitis | Diarrhea

Company: Incyte
Company Location: WILMINGTON DE 19803
Company CEO: Hervé Hoppenot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ruxolitinib

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 119

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Anemia|Dermatitis, Atopic|Graft vs Host Disease|Myelodysplastic Syndrome|Myelofibrosis|Neurodermatitis|Polycythemia Vera|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prurigo|Thrombocythemia, Essential|Thrombocytosis|Thrombosis|Vitiligo

Phase 2: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Adenocarcinoma|Anemia, Aplastic|Blast Crisis|Breast Cancer|Bronchiolitis Obliterans|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Clear Cell Adenocarcinoma|Colorectal Cancer|Dermatitis|Dermatitis, Seborrheic|Endometrioid Carcinoma|Eosinophilia|Exanthema|Fallopian Tube Cancer|Hepatitis B, Chronic|Hepatomegaly|Hidradenitis Suppurativa|Hodgkin Lymphoma|Hypereosinophilic Syndrome|Inflammatory Breast Cancer|Juvenile Myelomonocytic Leukemia,|Lichen Planus|Lichen Sclerosus et Atrophicus|Lung Cancer|Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic|Lymphohistiocytosis, Hemophagocytic|Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Multiple Myeloma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myeloproliferative Disorders|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cancer|Prostate Cancer|Serous Cystadenocarcinoma|Skin Manifestations|Stem Cell Transplant

Phase 1: Cachexia|Cytokine Release Syndrome|Healthy Volunteers|Non-Small-Cell Lung Cancer|Oncology Unspecified|Pancreatic Ductal Carcinoma|Wasting Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TRANSFORM-2

P3

Active, not recruiting

Myelofibrosis

2031-11-25

HEM-iSMART C

P2

Not yet recruiting

Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2031-10-01

2020-002071-35

P2

Active, not recruiting

Myelofibrosis

2030-10-26

INCB18424-370

P3

Not yet recruiting

Graft vs Host Disease

2030-10-20

Recent News Events

Date

Type

Title

01/13/2025

News Article

 Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

01/13/2025

News Article

 Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

01/13/2025

News Article

 Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

12/12/2024

News Article

 Ryvu Therapeutics provides an update on RVU120 Phase II program

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions